Status:
COMPLETED
In-practice Evaluation of Atacand 16mg Antihypertensive Effect
Lead Sponsor:
AstraZeneca
Conditions:
Essential Hypertension
Eligibility:
All Genders
18+ years
Brief Summary
The purpose of this study is to prove in practice the effectiveness of Atacand 16 mg in reducing blood pressure after 4 weeks of administration and the importance of administration of adequate doses
Eligibility Criteria
Inclusion
- Adult patients with mild (140-159/90-99 mgHg) to moderate (160-179/100-109 mmHg) essential hypertension, already treated with Atacand 8mg for 2-4 weeks, who have not reached the blood pressure treatment goal at least \<140/90 mgHg and the doctor has decided
- Signed and dated Patient Informed Consent (ICF)
Exclusion
- Hypersensitivity to the active substance or to any of the excipients of Atacand.
Key Trial Info
Start Date :
November 1 2008
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
January 1 2009
Estimated Enrollment :
400 Patients enrolled
Trial Details
Trial ID
NCT00802542
Start Date
November 1 2008
End Date
January 1 2009
Last Update
December 3 2010
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Research site
Daugavpils, Latvia
2
Research site
Jelgava, Latvia
3
Research site
Liepāja, Latvia
4
Research Site
Riga, Latvia